Targets of histone deacetylase inhibitors in ovarian cancer identified using proteome integral solubility alteration
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive Plus
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Cell Suspension Culture, Epithelial Cell, Cell Culture
DISEASE(S): Acute Leukemia,Malignant Neoplasm Of Ovary
SUBMITTER: 
Jolene Duda
LAB HEAD: Stefani Thomas
PROVIDER: PXD055375 | Pride | 2024-12-19
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| PISA_ES-2_F1.raw | Raw | |||
| PISA_ES-2_F10.raw | Raw | |||
| PISA_ES-2_F11.raw | Raw | |||
| PISA_ES-2_F12.raw | Raw | |||
| PISA_ES-2_F13.raw | Raw |
Items per page: 5 1 - 5 of 339 |
Similar Datasets
Project description:Most drugs used in the clinic and drug candidates target multiple proteins, and thus detailed characterization of their efficacy targets is required. While current methods rely on quantitative measurements at thermodynamic equilibrium, kinetic parameters such as the residence time of a drug on its target provide a better proxy for efficacy in vivo. Here, we present a new Residence Time Proteome Integral Solubility Alteration (ResT-PISA) assay which provides monitoring temporal protein solubility profiles after drug removal in either cell lysate or intact cells, quantifying the lifetime of the drug-target interaction. A compressed version of the assay measures the integral under the off-curve and enables the multiplexing of binding affinity proxy measurements with residence time assessment into a single proteomic analysis. We introduce a combined scoring system for three parametric dimensions to improve prioritization of targets. By providing complementary information to other characteristics of drug-target interaction, ResT-PISA approach can become a useful tool in drug development and precision medicine.
2023-01-06 | PXD034351 | Pride
Project description:Proteins are the primary targets of almost all small molecule drugs. However, even the most selectively designed drugs can potentially target several unknown proteins. Identification of potential drug targets can facilitate design of new drugs and repurposing of existing ones. Current state-of-the-art proteomics methodologies enable screening of thousands of proteins against a limited number of drug molecules. Here we report the development of a label-free quantitative proteomics approach that enables proteome-wide screening of small organic molecules in a scalable, reproducible, and rapid manner by streamlining the proteome integral solubility alteration (PISA) assay. We used rat organs ex-vivo to determine organ specific targets of medical drugs and enzyme inhibitors to identify novel drug targets for common drugs such as Ibuprofen. Finally, global drug profiling revealed overarching trends of how small molecules affect the proteome through either direct or indirect protein interactions.
2024-10-16 | PXD050784 | Pride
Project description:The One Health initiative connects human and animal health with their shared environment. The development of novel methodology to unbiased identification of mechanisms of action of chemicals and chemicals mixtures would address one of today´s challenges of environmental and human toxicology. Zebrafish embryos offer a unique opportunity to explore the proteome integral solubility alteration (PISA) assay to study the proteins that increase or decrease their solubility as protein targets of the bioactive compounds in an organism at an developmental stage. We presented here 4 different applications of the PISA method in zebrafish embryo with different types of compounds of environmental and health concern: i) endocrine disrupting chemical, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to outline the pathways compromised under exposure; ii) complex chemical mixtures composed by TCDD + alpha-endosulfan + bisphenol A (BPA) previously studied in vitro cells lines to evaluate single chemical versus mixture; iii) novel compounds from blue-green circular economy to map the organismal response, and a iv) novel drug directed to anti-cancer activity in lymphoma models to discharge side-effects at non-target organs. Our results demonstrated the unique opportunities of PISA assay in zebrafish for toxicology. We remark some differences to its application for drug target deconvolution. First, we evaluate both targets arising from an increase in solubility and in those decreasing, as both would be involved in modulation the cellular functions. Second, the method could be applicable to bioactive compound before chemical characterization or a chemical mixture of unknown stoichiometry. Third, the results from zebrafish embryo could provide a first glimpse of unspecific interactions with proteins in non-target tissues.The introduction of PISA assay in toxi- and ecotoxicoproteomics offers high-resolution and throughput in support with the 3R, and 3M principles.
2022-02-28 | PXD021670 | Pride
Project description:Multifaceted interrogation of the proteome deepens the system-wide understanding of biological systems; however, mapping the redox changes in the proteome has so far been significantly less informative than expression and solubility/stability analyses. Here, we devise the first high-throughput redox proteomics approach integrated with expression analysis (REX) and combine it with Proteome Integral Solubility Alteration (PISA) assay. The whole PISA-REX experiment in three biological replicates is multiplexed in a single tandem mass tag set (TMTpro). For benchmarking this compact PISA-REX tool, we analyzed HCT116 cells treated with auranofin. Then we applied PISA-REX to study the targets of Pladienolide B in SW620 cells, proteome remodeling upon stimulation of human monocytes by interferon α, and to paired primary and metastatic colon cancer cells. Providing comprehensive multifaceted information on the proteome, the compact PISA-REX has the potential to become an industry-standard in proteomics and to open new windows into the biology of health and disease.
2024-08-10 | PXD042967 | Pride
Project description:Caspases are a family of proteins mostly known for their role in the activation of the apoptotic pathway leading to cell death. In the last decade, caspases have been found to fulfil other tasks regulating the cell phenotype independently to cell death. Microglia are the immune cells of the brain responsible for the maintenance of physiological brain functions but can also be involved in disease progression when overactivated. We have previously described non30 apoptotic roles of caspase-3 (CASP3) in the regulation of the inflammatory phenotype of microglial cells or pro-tumoral activation in the context of brain tumors. CASP3 can regulate protein functions by cleavage of their target and therefore could have multiple substrates. So far, identification of CASP3 substrates has been performed mostly in apoptotic conditions where CASP3 activity is highly upregulated and these approaches do not have the capacity to uncover CASP3 substrates at the physiological level. In our study, we aim at discovering highaffinity substrates of CASP3 involved in the normal regulation of the cell. We used an unconventional approach by chemically reducing the basal level activity of CASP3 (by DEVD38 fmk treatment) coupled to a Mass Spectrometry screen (PISA) to identify stabilized, and consequently, non-cleaved proteins in microglia cells. PISA identified several significantly stabilized proteins after DEVD-fmk treatment, including a few already known CASP3substrates which validated our approach. Among them, we focused on the Collectin12 (COLEC12 or CL-P1) transmembrane receptor and uncovered a potential role for CASP3 cleavage of COLEC12 in the regulation of the phagocytic capacity of microglial cells. Taken together, these findings suggest a new way to uncover non-apoptotic high-affinity substrates of CASP3 important for the modulation of microglia cell physiology.
2023-05-10 | PXD032835 | Pride
Project description:To simplify chemical risk assessment, the adverse outcome pathway (AOP) method has arisen as a framework to predict the impact of chemical exposure on human and environmental health. The development of this predictive tool requires knowledge of the molecular interaction between chemicals and protein targets. Here, we demonstrate that the identification and selection of a target candidate to develop adverse outcome pathways can be obtained by applying high-throughput identification of chemical targets by proteome integral solubility alteration (PISA) assay, followed by selecting the priority target candidate by an analytical hierarchy process. From 8 identified protein targets for TCDD from a soluble proteome extracted from hepatocytes, we selected the priority target for developing AOPs. Our combined methodologies provide identification of a molecular initiating event, essential knowledge to link molecular interaction to impact on health. The identification of chemical targets following a systematic analysis of chemical protein interaction by proteomics increases the high-throughput and reduces the traditional bias. The target selection eliminates conflicting criteria by applying a multiple-criteria decision-making analysis.
2023-03-11 | PXD033056 | Pride
Project description:The thermal shift assay is a robust method of discovering protein-ligand interactions by measuring the alterations in protein thermal stability under various conditions. Several thermal shift assays have been developed and their throughput has been advanced greatly by the rapid progress in tandem mass tag-based quantitative proteomics. A recent paper by Gaetani et al. (J Proteome Res 2019, 18 (11), 4027-4037) introduced proteome integral solubility alteration (PISA) assay, further increasing throughput and simplifying the data analysis. Yet, it remains unclear how fold changes (integral treated samples versus integral control samples) perform in this assay. We show that fold changes have compromised linearity with ΔTm (shift in melting points) by simulation, and the magnitudes of the fold changes are inherently small in PISA assay, which is a challenge for quantitation. Both simulation and experimental results show that the selection of heating temperatures can tackle the small fold change problem and improve the sensitivity and specificity of the PISA assay.
2020-04-06 | PXD017346 | Pride
Project description:Cancer remains a significant global health challenge, necessitating the development of innovative and cost-effective treatments. Drug repurposing, particularly of cardiac glycosides (CGs), offers a promising strategy to expedite the discovery of anti-tumor drugs. This study employs proteome integral solubility alteration (PISA) to investigate the multifaceted mechanisms of action of CGs, including digoxin, digitoxin, and ouabain. Our study revealed that CGs may interact with a spectrum of proteins associated with cellular metabolism, ribosomal function, and apoptosis, suggesting a complex interplay between these pathways in cancer cells. Besides, it suggests that CGs could be repurposed to target cancer through a multifaceted approach that disrupts cellular metabolism, protein synthesis, and mitochondrial function. Further studies are warranted to confirm the functional implications of these interactions and to explore the therapeutic potential of CGs in cancer treatment.
2024-05-31 | PXD052740 |
Project description:Unbiased drug target engagement deconvolution and mechanism of action elucidation are major challenges in drug development. Modification-free target engagement methods, such as thermal proteome profiling, have gained increasing popularity over the last several years. However, these methods have limitations, and, in any case, new orthogonal approaches are needed. Here we present a novel isothermal method for comprehensive characterization of protein solubility alterations using the effect on protein solubility of cations and anions in the Hofmeister series. We combine this ion-based protein precipitation approach with Proteome Integrated Solubility Alteration (PISA) analysis and use this I-PISA assay to delineate the targets of several anti-cancer drugs both in cell lysate and in living cells. Lastly, we demonstrate that I-PISA can detect solubility changes in minute amounts of sample, opening chemical proteomics applications to small and rare biological material.
2022-06-09 | PXD030695 | Pride
Project description:Unbiased drug target engagement deconvolution and mechanism of action elucidation are major challenges in drug development. Modification-free target engagement methods, such as thermal proteome profiling, have gained increasing popularity over the last several years. However, these methods have limitations, and, in any case, new orthogonal approaches are needed. Here we present a novel isothermal method for comprehensive characterization of protein solubility alterations using the effect on protein solubility of cations and anions in the Hofmeister series. We combine this ion-based protein precipitation approach with Proteome Integrated Solubility Alteration (PISA) analysis and use this I-PISA assay to delineate the targets of several anti-cancer drugs both in cell lysate and in living cells. Lastly, we demonstrate that I-PISA can detect solubility changes in minute amounts of sample, opening chemical proteomics applications to small and rare biological material.
2022-06-09 | PXD033081 | Pride